您的位置：首页 > 产品中心 > SC-51089 hydrate
SC-51089 hydrate
产品别名
SC-51089 hydrate
8-Chloro-dibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide monohydrochloride hydrate
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C22H19ClN4O3·HCl · xH2O |
| Molecular weight | 459.33 (anhydrous basis) |
| MDL number | MFCD17215974 |
| PubChem Substance ID【PubChem化学物质编号】 | 329823723 |
| NACRES | NA.77 |
| Biochem/physiol Actions【生化/生理作用】 | SC-51089 is a selective EP1 prostanoid receptor antagonist. |
| Features and Benefits【特点和优势】 | This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here. |
| Legal Information【法律信息】 | Sold for research purposes under agreement from Pfizer Inc. Pfizer is a registered trademark of Pfizer, Inc. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| manufacturer/tradename | Pfizer® |
| color【颜色】 | white to off-white |
| solubility【溶解性】 | DMSO: ≥10 mg/mL |
| originator【创始人】 | Pfizer |
| storage temp.【储存温度】 | room temp |
| SMILES string | O.Cl.Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc4ccncc4)c2c1 |
| InChI | 1S/C22H19ClN4O3.ClH.H2O/c23-17-6-7-20-18(13-17)27(14-16-3-1-2-4-19(16)30-20)22(29)26-25-21(28)8-5-15-9-11-24-12-10-15;;/h1-4,6-7,9-13H,5,8,14H2,(H,25,28)(H,26,29);1H;1H2 |
| InChI key | UEAWIGPAXPGSJC-UHFFFAOYSA-N |
| packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
| Pictograms【象形图】 | GHS06 |
| Signal word【警示用语：】 | Danger |
| Hazard Statements | H301 - H315 - H319 - H335 |
| Precautionary Statements | P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Classifications【危险分类】 | Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3 |
| Target Organs【靶器官】 | Respiratory system |
| Storage Class Code【储存分类代码】 | 6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects |
| WGK | WGK 3 |
